Samlyn Capital’s Cidara Therapeutics CDTX Stock Holding History

Samlyn Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-307,960	Closed	-$29.5M	–	80
2025 Q3	$29.5M	Buy	+307,960	New	+$19.7M	0.41%	59

Other funds holding CDTX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Samlyn Capital's CDTX Position: Q4 2025 in Review

Samlyn Capital sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 307,960 shares — an estimated $29.5M sold.

Samlyn Capital first reported a position in CDTX in Q3 2025 and held it in 1 quarter. The position peaked at $29.5M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

Samlyn Capital reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
Samlyn Capital sold 307,960 Cidara Therapeutics shares in Q4 2025, an estimated $29.5M.
Samlyn Capital first reported a position in Cidara Therapeutics in Q3 2025 and held it in 1 quarter.
Samlyn Capital's Cidara Therapeutics position peaked at $29.5M in Q3 2025.
255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Samlyn Capital's 13F filing for Q4 2025, filed 17 Feb 2026.